Abstract
Long noncoding RNAs (lncRNAs) constitute the largest class of noncoding RNAs and play significant roles in the development of cardiovascular pathologies. In the present study, we aimed to evaluate whether 4 candidate lncRNAs – MIAT, MEG3, MALAT1, and MCM3AP-AS1 – have distinct expression levels in patients with obstructive coronary artery disease (CAD) and reveal the diagnostic and therapeutic potentials of these lncRNAs for CAD. A total of 90 patients who subjected to coronary angiography were enrolled. Relative expression of lncRNAs were assayed using qRT-PCR methodology. As a result, MIAT was downregulated, while MEG3 was upregulated in CAD patients. Receiver operating characteristic curves demonstrated that these lncRNAs have a high potential to provide sensitive and specific diagnosis of CAD. The calculated area under curve levels indicated that MIAT and MEG3 have high diagnostic value for detecting the presence of significant CAD. However, MALAT1 and MCM3AP-AS1 levels were not sufficiently reliable for CAD development in our cases. Here, we demonstrate that MIAT and MEG3 were differentially expressed in our patients and might be promising biomarkers and therapeutic targets for CAD. These results indicate that MIAT and MEG3 could play chief roles in CAD development.
References
1.
Ang
CE
, Trevino
AE
, Chang
HY
. Diverse lncRNA mechanisms in brain development and disease
. Curr Opin Genet Dev
. 2020
;65
:42
–6
. 2.
Arman
K
, Saadat
KASM
, Igci
YZ
, Bozgeyik
E
, Ikeda
MA
, Cakmak
EA
, Long noncoding RNA ERICD interacts with ARID3A via E2F1 and regulates migration and proliferation of osteosarcoma cells
. Cell Biol Int
. 2020
;44
(11
):2263
–74
. 3.
Arslan
S
, Berkan
Ö
, Lalem
T
, Özbilüm
N
, Göksel
S
, Korkmaz
Ö
, Long non-coding RNAs in the atherosclerotic plaque
. Atherosclerosis
. 2017
;266
:176
–81
. 4.
Dai
W
, Zeng
W
, Lee
D
. lncRNA MCM3AP-AS1 inhibits the progression of colorectal cancer via the miR-19a-3p/FOXF2 axis
. J Gene Med
. 2021
;23
(3
):e3306
. 5.
Dhanoa
JK
, Sethi
RS
, Verma
R
, Arora
JS
, Mukhopadhyay
CS
. Long non-coding RNA: its evolutionary relics and biological implications in mammals: a review
. J Anim Sci Technol
. 2018
;60
:25
. 6.
DiStefano
JK
. The emerging role of long noncoding RNAs in human disease
. Methods Mol Biol
. 2018
;1706
:91
–110
. 7.
Erdmann
J
, Kessler
T
, Munoz Venegas
L
, Schunkert
H
. A decade of genome-wide association studies for coronary artery disease: the challenges ahead
. Cardiovasc Res
. 2018
;114
(9
):1241
–57
. 8.
Frank
S
, Aguirre
A
, Hescheler
J
, Kurian
L
. A lncRNA Perspective into (Re)Building the Heart
. Front Cell Dev Biol
. 2016
;4
:128
. 9.
Ishii
N
, Ozaki
K
, Sato
H
, Mizuno
H
, Susumu Saito
S
, Takahashi
A
, Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction
. J Hum Genet
. 2006
;51
(12
):1087
–99
. 10.
Jia
Z
, Li
W
, Bian
P
, Liu
H
, Pan
D
, Dou
Z
. LncRNA MCM3AP-AS1 Promotes Cell Proliferation and Invasion Through Regulating miR-543-3p/SLC39A10/PTEN Axis in Prostate Cancer
. Onco Targets Ther
. 2020
;13
:9365
–76
. 11.
Khandelwal
A
, Bacolla
A
, Vasquez
KM
, Jain
A
. Long non-coding RNA: A new paradigm for lung cancer
. Mol Carcinog
. 2015
;54
(11
):1235
–51
. 12.
Khera
AV
, Kathiresan
S
. Genetics of coronary artery disease: discovery, biology and clinical translation
. Nat Rev Genet
. 2017
;18
(6
):331
–44
. 13.
Li
X
, Yu
M
, Yang
C
. YY1-mediated overexpression of long noncoding RNA MCM3AP-AS1 accelerates angiogenesis and progression in lung cancer by targeting miR-340-5p/KPNA4 axis
. J Cell Biochem
. 2020
;121
(3
):2258
–67
. 14.
Liao
YY
, Chen
ZY
, Wang
YX
, Lin
Y
, Yang
F
, Zhou
QL
. New progress in angiogenesis therapy of cardiovascular disease by ultrasound targeted microbubble destruction
. Biomed Res Int
. 2014
;2014
:872984
. 15.
Libby
P
, Buring
JE
, Badimon
L
, Hansson
GK
, Deanfield
J
, Bittencourt
MS
, Atherosclerosis
. Nat Rev Dis Primers
. 2019
;5
(1
):56
. 16.
Lu
T
, Wang
Y
, Chen
D
, Liu
J
, Jiao
W
. Potential clinical application of lncRNAs in non-small cell lung cancer
. Onco Targets Ther
. 2018
;11
:8045
–52
. 17.
Ma
X
, Luo
J
, Zhang
Y
, Sun
D
, Lin
Y
. LncRNA MCM3AP-AS1 Upregulates CDK4 by Sponging miR-545 to Suppress G1 Arrest in Colorectal Cancer
. Cancer Manag Res
. 2020
;12
:8117
–24
. 18.
Michalik
KM
, You
X
, Manavski
Y
, Doddaballapur
A
, Zörnig
M
, Braun
T
, Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth
. Circ Res
. 2014
;114
(9
):1389
–97
. 19.
Nandwani
A
, Rathore
S
, Datta
M
. LncRNAs in cancer: Regulatory and therapeutic implications
. Cancer Lett
. 2021
;501
:162
–71
. 20.
Potz
BA
, Parulkar
AB
, Abid
RM
, Sodha
NR
, Sellke
FW
. Novel molecular targets for coronary angiogenesis and ischemic heart disease
. Coron Artery Dis
. 2017
;28
(7
):605
–13
. 21.
Pranavchand
R
, Reddy
BM
. Current status of understanding of the genetic etiology of coronary heart disease
. J Postgrad Med
. 2013
;59
(1
):30
–41
. 22.
Qiu
L
, Ma
Y
, Yang
Y
, Ren
X
, Wang
D
, Jia
X
. Pro-angiogenic and pro-inflammatory regulation by lncRNA MCM3AP-AS1-mediated upregulation of DPP4 in clear cell renal cell carcinoma
. Front Oncol
. 2020
;10
:705
. 23.
Quan
W
, Hu
PF
, Zhao
X
, Lianhua
CG
, Batu
BR
. Expression level of lncRNA PVT1 in serum of patients with coronary atherosclerosis disease and its clinical significance
. Eur Rev Med Pharmacol Sci
. 2020
;24
(11
):6333
–7
. 24.
Sayols-Baixeras
S
, Lluís-Ganella
C
, Lucas
G
, Elosua
R
. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants
. Appl Clin Genet
. 2014
;7
:15
–32
. 25.
Sohrabifar
N
, Ghaderian
SMH
, Alipour Parsa
S
, Ghaedi
H
, Jafari
H
. Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus
. Arch Physiol Biochem
. 2020
:1
–8
. 26.
Sun
H
, Wu
P
, Zhang
B
, Wu
X
, Chen
W
. MCM3APAS1 promotes cisplatin resistance in gastric cancer cells via the miR138/FOXC1 axis
. Oncol Lett
. 2021
;21
(3
):211
. 27.
Tang
TT
, Wang
BQ
. Clinical significance of lncRNA-AWPPH in coronary artery diseases
. Eur Rev Med Pharmacol Sci
. 2020
;24
(22
):11747
–51
. 28.
Toraih
EA
, El-Wazir
A
, Alghamdi
SA
, Alhazmi
AS
, El-Wazir
M
, Abdel-Daim
MM
, Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events
. Genet Mol Biol
. 2019
;42
(3
):509
–18
. 29.
Wang
H
, Gong
H
, Liu
Y
, Feng
L
. Relationship between lncRNA-Ang362 and prognosis of patients with coronary heart disease after percutaneous coronary intervention
. Biosci Rep
. 2020
;40
(7
):BSR20201524
. 30.
Wen
J
, Han
S
, Cui
M
, Wang
Y
. Long noncoding RNA MCM3APAS1 drives ovarian cancer progression via the microRNA1433p/TAK1 axis
. Oncol Rep
. 2020
;44
(4
):1375
–84
. 31.
Wu
Z
, He
Y
, Li
D
, Fang
X
, Shang
T
, Zhang
H
, Long noncoding RNA MEG3 suppressed endothelial cell proliferation and migration through regulating miR-21
. Am J Transl Res
. 2017
;9
(7
):3326
–35
.32.
Yan
B
, Yao
J
, Liu
JY
, Li
XM
, Wang
XQ
, Li
YJ
, lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA
. Circ Res
. 2015
;116
(7
):1143
–56
. 33.
Yu
B
, Wang
S
. Angio-LncRs: LncRNAs that regulate angiogenesis and vascular disease
. Theranostics
. 2018
;8
(13
):3654
–75
. 34.
Zhang
X
, Wang
W
, Zhu
W
, Dong
J
, Cheng
Y
, Yin
Z
, Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels
. Int J Mol Sci
. 2019
;20
(22
):5573
. 35.
Zhong
W
, Deng
Q
, Deng
X
, Zhong
Z
, Hou
J
. Long non-coding RNA expression profiles in peripheral blood mononuclear cells of patients with coronary artery disease
. J Thorac Dis
. 2020
;12
(11
):6813
–25
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
